From lipodystrophy to cardiovascular disease: new insight into the management of HIV infection (Q58798012)

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

Changes in the risk of death after HIV seroconversion compared with mortality in the general population

21 January 2018

1 reference

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

21 January 2018

1 reference

Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review

21 January 2018

1 reference

Effects of recombinant growth hormone on visceral fat accumulation: pilot study in human immunodeficiency virus-infected adolescents

21 January 2018

1 reference

Recombinant human growth hormone therapy in HIV-associated wasting and visceral adiposity

21 January 2018

1 reference

"Buffalo hump" in men with HIV-1 infection.

21 January 2018

1 reference

Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors.

21 January 2018

1 reference

Fat distribution in men with HIV infection

21 January 2018

1 reference

Therapeutic approaches to combating lipoatrophy: do they work?

21 January 2018

1 reference

Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report

21 January 2018

1 reference

Clinical assessment of HIV-associated lipodystrophy in an ambulatory population

21 January 2018

1 reference

HIV lipodystrophy: prevalence, severity and correlates of risk in Australia

21 January 2018

1 reference

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy

21 January 2018

1 reference

The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition

21 January 2018

1 reference

Fat distribution in women with HIV infection

21 January 2018

1 reference

The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men.

21 January 2018

1 reference

Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study

21 January 2018

1 reference

Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).

21 January 2018

1 reference

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

21 January 2018

1 reference

Effect of early versus deferred antiretroviral therapy for HIV on survival

21 January 2018

1 reference

Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.

21 January 2018

1 reference

HIV and metabolic syndrome: a comparison with the general population.

21 January 2018

1 reference

Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease

21 January 2018

1 reference

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

Ischemic Heart Disease in HIV-Infected and HIV-Uninfected Individuals: A Population-Based Cohort Study

21 January 2018

1 reference

Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City

21 January 2018

1 reference

State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary

21 January 2018

1 reference

Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy

21 January 2018

1 reference

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

21 January 2018

1 reference

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

21 January 2018

1 reference

HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy

21 January 2018

1 reference

Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms

21 January 2018

1 reference

Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities

21 January 2018

1 reference

CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection

21 January 2018

1 reference

T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy

21 January 2018

1 reference

HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity

21 January 2018

1 reference

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.

21 January 2018

1 reference

The Role of Immune Reconstitution in the Onset of Subclinical Atheromasic Lesions

21 January 2018

1 reference

Coronary aging in HIV-infected patients

21 January 2018

1 reference

Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort

21 January 2018

1 reference

Impact of HIV infection and HAART on serum lipids in men.

21 January 2018

1 reference

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

21 January 2018

1 reference

High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

21 January 2018

1 reference

HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.

21 January 2018

1 reference

HIV infection and high density lipoprotein metabolism

21 January 2018

1 reference

Human immunodeficiency virus impairs reverse cholesterol transport from macrophages

21 January 2018

1 reference

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk

21 January 2018

1 reference

Lipid and apoprotein profile in HIV-1-infected patients after CD4-guided treatment interruption

21 January 2018

1 reference

HIV infection and abnormal regional ventricular function

21 January 2018

1 reference

Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy

21 January 2018

1 reference

Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors

21 January 2018

1 reference

Cardiovascular complications in HIV management: past, present, and future

21 January 2018

1 reference

Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients

21 January 2018

1 reference

Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study

21 January 2018

1 reference

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

21 January 2018

1 reference

Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults

21 January 2018

1 reference

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

21 January 2018

1 reference

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

21 January 2018

1 reference

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

21 January 2018

1 reference

Impact of nevirapine on lipid metabolism

21 January 2018

1 reference

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

21 January 2018

1 reference

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

21 January 2018

1 reference

Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease

21 January 2018

1 reference

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

21 January 2018

1 reference

Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses

21 January 2018

1 reference

Endothelial adhesion molecules are associated with inflammation in subjects with HIV disease.

21 January 2018

1 reference

Plasma levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls.

21 January 2018

1 reference

Endothelial function in HIV-infected persons.

21 January 2018

1 reference

Current update on HIV-associated vascular disease and endothelial dysfunction

21 January 2018

1 reference

Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction

21 January 2018

1 reference

Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.

21 January 2018

1 reference

Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy

21 January 2018

1 reference

Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection

21 January 2018

1 reference

Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy

21 January 2018

1 reference

Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection

21 January 2018

1 reference

Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure

21 January 2018

1 reference

Carotid intima-media thickness in HIV patients treated with antiretroviral therapy

21 January 2018

1 reference

Predictive factors of vascular intima media thickness in HIV-positive subjects

21 January 2018

1 reference

Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men.

21 January 2018

1 reference

Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis

21 January 2018

1 reference

HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies.

21 January 2018

1 reference

Aortic stiffness in untreated adult patients with human immunodeficiency virus infection

21 January 2018

1 reference

Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients

21 January 2018

1 reference

Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects

21 January 2018

1 reference

Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo

21 January 2018

1 reference

Association of HIV viral load with monocyte chemoattractant protein-1 and atherosclerosis burden measured by magnetic resonance imaging

21 January 2018

1 reference

Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study

21 January 2018

1 reference